Financial Analyst Summary: Bal Pharma Limited Regulatory Response
Date and Nature of Exchange Communication
Bal Pharma Limited responded to the National Stock Exchange of India Limited regarding multiple emails dated 22 June 2026, 02 July 2026, and 20 July 2026. The exchange sought clarification on variations observed between the financial results submitted in XBRL format and the corresponding PDF financial statements, specifically concerning Standalone Profit After Tax (PAT), Standalone Earnings Per Share (EPS), and both Standalone and Consolidated Cash Flow Statements for the financial year ended 31 March 2026.
Company's Clarification on Trading Volume and Financial Results
The company clarified that the financial results approved by the Board of Directors and reviewed/audited by the Statutory Auditors, as contained in the PDF format, represent the final and correct financial results. The variations in the earlier XBRL submissions were attributed to technical and validation-related aspects of the XBRL filing utility, including how certain figures and derived values were captured and rounded off during the filing process.
To address these discrepancies, Bal Pharma Limited refiled both the Standalone and Consolidated Financial Results in XBRL format. The company confirmed that the revised XBRL submissions have been aligned with and now match the corresponding figures reported in the previously submitted PDF financial results.
Key confirmations provided:
- There has been no change or revision in the financial results approved by the Board of Directors.
- The PDF financial statements remain the final and approved results.
- The refiled XBRL figures now match the PDF results with no inconsistencies.
- The underlying financial information remains unchanged.
- The company will exercise additional care in future filings to ensure reconciliation between XBRL submissions and approved financial statements.
Reference to Regulatory Compliance
The communication references compliance with SEBI Listing Obligations and Disclosure Requirements, specifically Regulation 30, regarding the disclosure of material events. The company's response demonstrates adherence to regulatory requirements for accurate financial reporting and timely response to exchange queries.
Details of Financial Results
The audited financial results for the quarter and year ended 31 March 2026 were approved by the Board of Directors in a meeting held on 27 May 2026. Key financial highlights include:
Standalone Financial Position (as at 31 March 2026):
- Total Assets: ₹39,105.51 lakhs (vs. ₹35,056.39 lakhs in FY2025)
- Total Equity: ₹10,409.91 lakhs
- Total Liabilities: ₹24,330.15 lakhs
Standalone Performance (Year ended 31 March 2026):
- Profit Before Tax: ₹636.52 lakhs (vs. ₹573.23 lakhs in FY2025)
- Net Cash from Operating Activities: ₹3,083.38 lakhs
Consolidated Performance (Year ended 31 March 2026):
- Total Income: ₹31,358.91 lakhs
- Profit Before Tax: ₹593.38 lakhs
- Net Profit: ₹632.00 lakhs
- Basic EPS: ₹3.95
The Board also recommended a dividend of ₹1.20 per equity share (12%) subject to shareholder approval at the ensuing Annual General Meeting.
Additional Corporate Actions
During the 27 May 2026 Board meeting, several corporate actions were approved:
- Appointment of Murugesh & Co as Internal Auditors
- Appointment of G.N.V & Associates as Cost Auditors for FY2025-26
- Grant of 500,000 stock options to employees under the Employee Stock Option Plan-2025
- Preferential issue of 1,000,000 warrants to promoters
- Appointment of Mr. Shreepada M L (M# A66681) as Company Secretary and Compliance Officer